Gregory K. Behbehani

Hematology
460 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.

Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.

Journal: Journal for immunotherapy of cancer
Published: June 24, 2026

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Journal: Blood cancer discovery
Published: May 18, 2026

Differential Correlation Across Subpopulations of Single Cells in Subtypes of Acute Myeloid Leukemia.

Differential Correlation Across Subpopulations of Single Cells in Subtypes of Acute Myeloid Leukemia.

Journal: Biotech (Basel (Switzerland))
Published: May 14, 2026

Erratum: Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.

Erratum: Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.

Journal: Molecular therapy. Oncology
Published: February 09, 2026

In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages.

In vitro generated macrophages reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages.

Journal: Oncoimmunology
Published: January 26, 2026

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.

Journal: Molecular therapy. Oncology
Published: October 15, 2025

circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias.

circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias.

Journal: Blood
Published: August 18, 2025

CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma.

CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma.

Journal: Molecular therapy. Oncology
Published: July 25, 2025

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML.

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML.

Journal: Blood neoplasia
Published: January 09, 2025

Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer.

Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer.

Journal: Cancer immunology research
Published: August 13, 2024

circPCMTD1 : A protein-coding circular RNA that regulates DNA damage response in BCR/ABL -positive leukemias.

circPCMTD1 : A protein-coding circular RNA that regulates DNA damage response in BCR/ABL -positive leukemias.

Journal: bioRxiv : the preprint server for biology
Published: July 15, 2024

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.

Journal: Blood neoplasia
Published: April 22, 2024
Showing 1-12 of 62

Last Updated: 09/26/2026